Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Anti-malarial P218 shows promising result in the preclinical study
a:3:{s:6:"locale";s:5:"en_GB";s:3:"rtl";i:0;s:9:"flag_code";s:2:"gb";}
